During the first two months of 2014, $4.06 billion were placed in healthcare exchange traded funds in the U.S., largely due to the biotechnology and pharmaceutical sectors, according to a Bloomberg report.
That dollar amount is 51 percent of the money in all U.S. sector-focused ETFs, and it is coming in at the fastest rate in six years, according to the report.
Nine of the top ten largest holdings in three sector funds are drug and biotech companies, according to the report.
Forecasters thought the Patient Protection and Affordable Care Act and patent issues would have slowed this sector, but this has proved to not be the case.
"The big pharmas are managing through [patent issues] really well and they have pipelines that look better than people were thinking," said Tony Scherrer, director of research at Smead Capital Management, in the report.
More Articles on Pharmaceuticals:
Pharmaceutical Companies Spending Less on Promotional Drug Speakers
Hepatitis C Drug Costs More Than 1K a Pill
Pacira Pharmaceuticals Becomes NPSF Coalition Member